HHS Overrules FDA Scientists, Approves Six Peptides for Compounding
The Department of Health and Human Services has permitted six experimental peptides to be compounded by licensed pharmacies and doctors, despite objections from FDA career scientists.
In a significant move that has sparked debate within the medical community, the Department of Health and Human Services (HHS) has approved six experimental peptides for compounding by licensed pharmacies and physicians, a decision that reportedly came despite objections from FDA career scientists 12345.
This development marks a notable shift in the regulatory landscape, as it is typically the FDA that makes decisions regarding compounding under normal circumstances 3. However, the HHS’s recent policy change now directs the FDA not to take action against pharmacies selling these peptides, which are used for wellness purposes 34.
The six peptides in question include BPC-157 and TB-500, and they are now covered under a new policy that includes safety measures such as requiring their ingredients to come from FDA-registered factories 345. This is particularly noteworthy because, under standard FDA rules, these peptides would be classified as illegal drugs 34.
The decision by HHS to allow the compounding of these peptides comes at a time when the FDA had recently added several peptides to its list of substances that should not be compounded due to safety risks 35. This move by the FDA in 2023 highlights the ongoing tension between the two agencies over the regulation of these compounds.
Kennedy, a notable figure in the field, described using BPC-157 to treat a muscle injury, illustrating one potential application of these peptides 3. The approval by HHS opens up new possibilities for patients seeking alternative treatments, while also raising questions about the future of peptide compounding regulations.
What we know
- HHS allowed six experimental peptides to be compounded by licensed pharmacies and physicians. 134
- This decision was made despite objections from FDA career scientists. 12345
- The six peptides include BPC-157 and TB-500. 134
- The policy covers six specific peptides used for wellness purposes. 34
- The policy directs the FDA not to take action against pharmacies selling these peptides. 34
- Under normal FDA rules, these peptides would be considered illegal drugs. 34
- The policy includes safety measures such as requiring peptide ingredients from FDA-registered factories. 345
- Decisions about compounding have traditionally been made by the FDA, not HHS. 3
- In 2023, the FDA added several peptides to its list of substances that should not be compounded due to safety risks. 35
- Kennedy described using BPC-157 to treat a muscle injury. 3
Verification report
Likely accurate — probability of truth 77%, weighted across 10 claims from 5 independent outlets.
- confirmed HHS allowed six experimental peptides to be compounded by licensed pharmacies and physicians. (87%)
- confirmed This decision was made despite objections from FDA career scientists. (87%)
- confirmed The six peptides include BPC-157 and TB-500. (87%)
- likely The policy covers six specific peptides used for wellness purposes. (72%)
- likely The policy directs the FDA not to take action against pharmacies selling these peptides. (72%)
- likely Under normal FDA rules, these peptides would be considered illegal drugs. (72%)
- likely The policy includes safety measures such as requiring peptide ingredients from FDA-registered factories. (72%)
- likely Decisions about compounding have traditionally been made by the FDA, not HHS. (72%)
- likely In 2023, the FDA added several peptides to its list of substances that should not be compounded due to safety risks. (72%)
- likely Kennedy described using BPC-157 to treat a muscle injury. (72%)
Sources
- STAT — STAT+: HHS green lights six peptides, despite concerns from FDA scientists
https://www.statnews.com/2026/10/29/biotech-news-hhs-green-lights-six-peptides-for-now/?utm_campaign=rss - PBS NewsHour — AP report: FDA scientists opposed the Trump administration's move to ease peptides access
https://www.pbs.org/newshour/health/ap-report-fda-scientists-opposed-the-trump-administrations-move-to-ease-peptides-access - The Guardian Health — FDA scientists opposed Trump administration’s move to ease peptide access
https://www.theguardian.com/us-news/2026/oct/28/peptides-fda-health-human-services-department - Medical Xpress — RFK Jr. eases access to unproven peptides despite opposition from FDA scientists
https://medicalxpress.com/news/2026-10-rfk-jr-eases-access-unproven.html - ABC News U.S. — FDA scientists opposed the Trump administration's effort to ease peptides access
https://abcnews.com/US/wireStory/fda-scientists-opposed-trump-administrations-effort-ease-peptides-137644295